

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The combination of nivolumab/ipilimumab is FDA approved as first-line therapy for patients with _____ advanced RCC.

 - a. Favorable-risk
 - b. Intermediate-risk
 - c. Poor-risk
 - d. All of the above
 - e. Both a and b
 - f. Both b and c**
2. On the Phase III KEYNOTE-426 trial evaluating pembrolizumab in combination with axitinib versus sunitinib as first-line therapy for advanced RCC, the anti-PD-1/VEGF tyrosine kinase inhibitor (TKI) combination demonstrated a significant improvement in _____ versus sunitinib.

 - a. Overall survival
 - b. Progression-free survival
 - c. Response rates
 - d. All of the above**
 - e. Both b and c
3. Which of the following categories best reflects the mechanism of action of atezolizumab?

 - a. Anti-PD-1 antibody
 - b. Anti-PD-L1 antibody**
 - c. VEGF TKI
4. On the Phase III JAVELIN Renal 101 trial evaluating _____ in combination with axitinib versus sunitinib as first-line therapy for advanced RCC, the anti-PD-L1/VEGF TKI combination demonstrated a significant improvement in progression-free survival and response rates.

 - a. Atezolizumab
 - b. Avelumab**
 - c. Nivolumab
5. Which of the following axitinib-containing regimens is FDA approved as first-line therapy for patients with advanced RCC?

 - a. Avelumab/axitinib
 - b. Pembrolizumab/axitinib
 - c. Both a and b**
 - d. Neither a nor b